Press Releases
Dec. 22, 2016 biOasis Announces Adoption of Restricted Share Unit Plan
VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”) announces that subject to approval by the TSX Venture Exchange (“TSXV”) and ratification by the Company’s shareholders at the 2016 Annual and Special General Meeting of shareholders (the “AGM”), the Company adopted a restricted share unit plan (the “RSU Plan”). Further details regarding the RSU… Read more »
Nov. 6, 2016 biOasis Attends BIO Europe and the Lockman BT2111 Paper is Honored by being Featured on the Cover of Pharmaceutical Research’s December Journal
VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today announced it’s team is attending BIO Europe, November 7th to 9th, in Cologne, Germany. In addition, the company announced that Dr. Paul Lockman’s recently published paper on biOasis’s… Read more »
Oct. 23, 2016 biOasis Engages Rising Tide Equity to Increase Global Awareness
VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today announced it has engaged Rising Tide Equity to increase its global awareness. Investors are increasingly using digital media and non-traditional media outlets to identify potential investment opportunities. Recent… Read more »
Sep. 20, 2016 biOasis Enters Into a License Agreement With Vaccinex Inc
Vancouver, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) (“biOasis”), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, today announced it has entered into a License Agreement (the “Agreement”) with Vaccinex Inc. (“Vaccinex”). Under the terms of the Agreement, Vaccinex will have the right to commercialize its… Read more »
Aug. 29, 2016 biOasis Announces Publication of Scientific Paper – Transcend-Based Anti-Cancer Antibody BT2111 Crosses the Blood-Brain Barrier and Shows Efficacy in the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brains of Animal Model
Vancouver, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today announced the publication of a peer-reviewed scientific paper detailing the results of an in-vivo study of the treatment of Metastatic HER2+ Breast Cancer brain tumors in an animal… Read more »
Jul. 10, 2016 biOasis Announces the Issuance of an Additional US Patent for The Delivery of Therapeutic Agents Across The Blood-Brain Barrier
Vancouver, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces the issuance of a US patent covering a refined subset of fragments found within Melanotransferrin or P97 for the delivery of therapeutic agents to the brain. The U.S.… Read more »
May. 17, 2016 biOasis Technologies Inc. to Present at BIO International Conference in San Francisco on June 7, 2016
biOasis to showcase their Transcend technology for the transport of drugs across the blood-brain barrier (BBB)
Apr. 21, 2016 biOasis Technologies Enters into a License Agreement with Astellas Research Institute of America LLC
Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI)(OTCQB: BIOAF)(the “Company”) announces that it has entered into a License Agreement to collaborate with Astellas Research Institute of America LLC (“Astellas”). The terms of the agreement, for competitive reasons, remain confidential, as do the specific therapeutic targets and work programs. The companies intend to collaborate on the… Read more »
Apr. 8, 2016 biOasis Technologies Inc. Grants Stock Options
Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI)(OTCQB: BIOAF)(the “Company”) announces that pursuant to the Company’s Incentive Stock Option Plan (the “Plan”), it has granted incentive stock options to directors, officers and consultants of the Company to purchase an aggregate of 1,950,000 common shares in the capital stock of the Company. The options are exercisable at… Read more »
Feb. 29, 2016 biOasis Announces Shares for Services Settlement
Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI)(OTCQB: BIOAF)(the “Company”) wishes to announce its intention to issue 125,000 shares for services to a consultant of the Company that provides certain consulting services related to business development and financial advisory services. The issuance of shares for services will represent payment of consulting fees. The consulting agreement… Read more »